The major proteins contributing to these associations were MYC, RAF1, JAK2, and PTEN. These findings suggest that agents that target these signaling pathways, such as ruxolitinib or sorafenib, could be effective in HS patients with a matching genetic profile. Here, RAF1 is linked to histiocytic sarcoma.